AI Signal Dashboard
Last updated: 04.30 01:34
Top Undervalued
+10.5¢
(No)
FDA approves Daiichi Sankyo & AstraZeneca's Enhertu? AI analysis: • +10.5¢ undervalued • Live Prediction Market fair value & mispricing alerts.
Undervalued Options Insights:
The current market price is 51. With less than 20 days until the expected FDA decision date, the mar...
🔓 Log in to see more
Real-time High Yield Opportunities
View MoreAll
Outcomes
Market
Price
AI Fair
Value
Value
Edge
YesNo
61.5¢
38.5¢
51¢
49¢
0¢
+10.5¢
⚠️ Risk Warning: Live data may lag! Prices can shift instantly due to news or low liquidity. Before trading, use AI Chat for [Live Recalculate], [Check Liquidity], [Trollbox Radar], or review [Fair Value Logic] to verify.
Hedging
AZN
4568.T
The FDA's decision on the new indication for Enhertu (neoadjuvant treatment of HER2-positive breast cancer) will directly impact the valuation and short-term stock prices of AstraZeneca (AZN) and Daiichi Sankyo (4568.T). A surprise rejection or approval could trigger noticeable tradable movements for both partnered companies.